Morgan Stanley lowered the firm’s price target on Haleon to 410 GBp from 415 GBp and keeps an Overweight rating on the shares. The firm updated its forecast ahead of the upcoming Q3 earnings results due on October 31. Specifically, Morgan Stanley lowered its Q3 forecast to +6.3%, down from +7.5%, as it expects “more challenging vitamins, minerals and supplements comps in the U.S. in particular.” The analyst added that they are looking for more clarity on ownership and continued business momentum from the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HLN:
- Haleon price target raised to 375 GBp from 340 GBp at Deutsche Bank
- Pfizer upsizes Haleon offering to 640M shares, Bloomberg says
- Pfizer intends to sell about 540M ordinary shares in Haleon
- Morgan Stanley removes Haleon as Top Pick, ups price target
- Haleon launches Eroxon gel for erectile dysfunction